Global Hyperphosphatemia Drugs Market 2011-2015

TechNavio's analysts forecast the Global Hyperphosphatemia Drugs market to grow at a CAGR of 12.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of chronic kidney disease. The Global Hyperphosphatemia Drugs market has also been witnessing the trend of an increasing number of strategic alliances among vendors. However, side effects caused by the hyperphosphatemia drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Hyperphosphatemia Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hyperphosphatemia Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Fresenius Medical Care AG & Co. KGaA, Shire plc, and Sanofi S.A.

Other vendors mentioned in the report: Keryx Biopharmaceuticals Inc., Novartis AG, Vifor Pharma AG, Astellas Pharma Inc., Panacor Bioscience Ltd., and Perrigo Co.

Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.

01. Executive Summary
02. Introduction
03. Market Coverage
Overview
Product Offerings
04. Market Landscape
Market Size
Five Forces AnalysiS
05. Geographical Segmentation
06. Key Leading Countries
USA
Japan
Germany
Economic Indicators of Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Sanofi S.A.
SWOT Analysis
15.2 Shire plc.
Business Overview
SWOT Analysis
15.3 Fresenius Medical Care AG & Co. KGaA
Business Overview
SWOT Analysis
16. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Hyperphosphatemia Drugs Market 2011-2015 (US$ million)
Exhibit 2: Global Hyperphosphatemia Drugs Market by Geographical Segmentation 2011
Exhibit 3: Global Hyperphosphatemia Drugs Market by Vendor Segmentation 2011